# China NMPA Drug Inspection - Anguo Jiuwang Pharmaceutical Co., Ltd. - Licorice tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anguo-jiuwang-pharmaceutical-co-ltd/c1fbf6ea-fa44-4c69-94d8-4f417b8c50f5/
Source feed: China

> China NMPA drug inspection for Anguo Jiuwang Pharmaceutical Co., Ltd. published December 23, 2021. Drug: Licorice tablets. The Hebei Provincial Drug Administration issued Bulletin No. 4 in December 2021, detailing results from its province-wid

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Hebei Province Drug Quality Bulletin (2021 Drug Supervision and Sampling Inspection No. 4)
- Company Name: Anguo Jiuwang Pharmaceutical Co., Ltd.
- Publication Date: 2021-12-23
- Drug Name: Licorice tablets
- Inspection Finding: The [content determination] item did not meet the requirements.
- Action Taken: The relevant drug regulatory authorities have taken control measures such as sealing and seizing in accordance with the law; they have filed cases to investigate the illegal acts of the aforementioned drug manufacturers in producing and selling substandard drugs, and have taken necessary risk control measures.
- Summary: The Hebei Provincial Drug Administration issued Bulletin No. 4 in December 2021, detailing results from its province-wide drug quality sampling program. During these inspections, Anguo Jiuwang Pharmaceutical Co., Ltd. was identified for producing substandard medicine. Specifically, a batch of Licorice tablets (Batch 20122607) failed the critical 'content determination' test, which evaluates whether the active ingredients meet the required potency and purity standards. These samples were collected from health service stations and pharmacies in the Hengshui region and verified by the Hengshui Comprehensive Inspection and Testing Center. In response to these findings, the regulatory authorities have operated under the Drug Administration Law of the People's Republic of China. Immediate enforcement actions include the seizure and sealing of the non-compliant drug batches. The provincial administration has directed local regulatory bodies to formally investigate and prosecute Anguo Jiuwang Pharmaceutical Co., Ltd., along with the distributors involved, for the production and sale of substandard pharmaceuticals. Furthermore, the authorities must implement risk control measures to protect public health and are required to publicly disclose the final disciplinary results within three months. If any evidence suggests the drugs were counterfeit or that criminal activity occurred, the cases will be referred to public security departments for further legal action. All findings and progress must be reported to the Hebei Provincial Drug Administration's inspection department to ensure comprehensive oversight and compliance with national safety standards.

Company: https://www.globalkeysolutions.net/companies/anguo-jiuwang-pharmaceutical-co-ltd/23da501f-0dd3-49f3-a50c-864eb527ba99/